Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Troy Ostrander

Family Medicine Belden, MS Doctor of Osteopathy

NPI 1437383718 CMS profile 201764

4637 Whitechapel Ln, Belden, MS 38826

Open in the dashboard

General payments

$2,077

149 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Troy Ostrander of Belden, MS is reported in the CMS Open Payments database as having received $2,077 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $211 12
2021 General $936 70
2020 General $345 23
2019 General $585 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Troy Ostrander
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Troy Ostrander were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Troy Ostrander Family Medicine median Middle half National median
2019 $585 $150 $41–$543 $163
2020 $345 $120 $32–$415 $114
2021 $936 $137 $35–$551 $132
2022 $211 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Novo Nordisk Inc $203 16 payments
  2. Janssen Pharmaceuticals, Inc $189 12 payments
  3. Amarin Pharma Inc. $174 19 payments
  4. GlaxoSmithKline, LLC. $168 10 payments
  5. Amgen Inc. $144 11 payments
  6. AbbVie, Inc. $140 11 payments
  7. AstraZeneca Pharmaceuticals LP $113 7 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $99 6 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $96 7 payments
  10. Sunovion Pharmaceuticals Inc. $91 8 payments
  11. Other $659 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,077 149 payments
Products named General payments · program years 2019–2022
  1. XARELTO $189 12 payments
  2. Ozempic $187 15 payments
  3. RYBELSUS $178 14 payments
  4. Vascepa $174 19 payments
  5. TRELEGY ELLIPTA $136 8 payments
  6. Repatha $124 10 payments
  7. AIMOVIG $124 10 payments
  8. VRAYLAR $91 8 payments
  9. JARDIANCE $85 5 payments
  10. Yupelri $80 5 payments
  11. Other $1,138 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 317 drugs

Part D claims

61,687

Median for Emergency Medicine: 88

Drug cost

$2,374,517

Median for Emergency Medicine: $590

Branded share of claims

17.1%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,071 $333,644
Jardiance Empagliflozin Brand 614 $155,928
Tradjenta Linagliptin Brand 388 $128,857
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 101 $70,686
Gemtesa Vibegron Brand 282 $70,086
Linzess Linaclotide Brand 107 $61,417
Xarelto Rivaroxaban Brand 160 $53,422
Entresto Sacubitril/Valsartan Brand 191 $48,190
Myrbetriq Mirabegron Brand 239 $36,418
Ozempic Semaglutide Brand 35 $35,926

The 10 drugs with the highest cost, of 317 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$249,501

Medicare's payments for the services billed

Medicare patients

614

Average age 76

Services billed

3,538

373 women, 241 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 66%
Arthritis 57%
Diabetes 51%
Alzheimer's or dementia 51%
Ischemic heart disease 42%
Heart failure 41%
Chronic kidney disease 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record